Evidence map›Paper›PMID 30562497›Full record

ArticleThe American journal of medicine2019

National Rate of Tobacco and Substance Use Disorders Among Hospitalized Heart Failure Patients.

Sarah C Snow, Gregg C Fonarow, Joseph A Ladapo, Donna L Washington, Katherine J Hoggatt, Boback Ziaeian

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Impact of multiple substance use on circulating ST2, a biomarker of adverse cardiac remodelling, in women.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sarah C SnowDivision of General Internal Medicine, David Geffen School of Medicine at University of California, Los Angeles.
Gregg C FonarowDivision of Cardiology, David Geffen School of Medicine at University of California, Los Angeles; Ahmanson-UCLA Cardiomyopathy Center, University of California,Los Angeles Medical Center.
Joseph A LadapoDivision of General Internal Medicine, David Geffen School of Medicine at University of California, Los Angeles.
Donna L WashingtonDivision of General Internal Medicine, David Geffen School of Medicine at University of California, Los Angeles; Division of Health Services Research & Development, Veterans Affairs Greater Los Angeles Healthcare System, Calif.
Katherine J HoggattDivision of Health Services Research & Development, Veterans Affairs Greater Los Angeles Healthcare System, Calif; Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles.
Boback ZiaeianDivision of Cardiology, David Geffen School of Medicine at University of California, Los Angeles; Division of Health Services Research & Development, Veterans Affairs Greater Los Angeles Healthcare System, Calif; Divisionof Cardiology, Veterans Affairs Greater Los Angeles Healthcare System, Calif. Electronic address: bziaeian@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

Financial incentive strategies for smoking cessation in high-risk, hospitalized patients.R01DA045688 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LADAPO, JOSEPH ABIODUN, SHERMAN, SCOTT E · 2019 to 2023
$3.8M
American Heart Association-American Stroke Association 17SDG33630113NIDA NIH HHS R01 DA045688
6 · The paper itself

Abstract

backgroundSeveral cardiotoxic substances impact heart failure incidence. The burden of comorbid tobacco or substance use disorders among heart failure patients is under-characterized. We describe the burden of tobacco and substance use disorders among hospitalized heart failure patients in the United States.

methodsWe calculated the proportion of primary heart failure hospitalizations in the 2014 National Inpatient Sample with tobacco or substance use disorders accounting for demographic factors.

resultsOf 989,080 heart failure hospitalizations, 15.5% (n = 152,965) had documented tobacco (n = 119,285, 12.1%) or substance (n = 61,510, 6.2%) use disorder. Female sex was associated with lower rates of tobacco (odds ratio [OR] 0.72; 95% confidence interval [CI], 0.70-0.74) and substance (OR 0.37; 95% CI, 0.36-0.39) use disorder. Tobacco and substance use disorder rates were highest for hospitalizations <55years of age. Native American race was associated with increased risk of alcohol use disorder (OR 1.67; 95% CI, 1.27-2.20) and black race with alcohol (OR 1.09; 95% CI, 1.02-1.16) or drug (OR 1.63; 95% CI, 1.53-1.74) use disorder. Medicaid insurance or income in the lowest quartile were associated with increased risk of tobacco and substance use disorders.

conclusionsTobacco and substance use disorders affect vulnerable heart failure populations, including those of male sex, younger age, lower socioeconomic status, and racial/ethnic minorities. Enhanced screening for tobacco and substance use disorders in hospitalized heart failure patients may reveal opportunities for treatment and secondary prevention.

Indexed as

AdultAgedAged, 80 and overFemaleHeart FailureHumansInpatientsMaleMiddle AgedSubstance-Related DisordersUnited StatesAlcoholDrug useHealth care disparitiesHeart failureHospitalizationSubstance useTobacco

Identifiers

PMID30562497
PMCPMC6615901
OpenAlexW2903848980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.